Middle East and Africa Anticoagulant Reversal Drug Market Opportunities by 2027

The anticoagulant reversal drug market in Middle East and Africa is expected to grow from US$ 34.5 million in 2019 to US$ 75.4 million by 2027; it is estimated to grow at a CAGR of 10.9% from 2019 to 2027.

Rapidly progressing research activities in drug development of novel therapeutics across the world to counter the growing prevalence of cardiovascular diseases, such as atrial fibrillation is driving the growth of the anticoagulant reversal drugs market. There is always a need for innovative therapeutic approaches in the treatment of various cardiovascular indications. For instance, the study titled ‘Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages,’ published in February 2020, to investigate the efficacy of andexanet alfa in the treatment of intracranial hemorrhages (ICH).

Similarly, ‘Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC),’ published in March 2019, attempted to compare the activity of different novel reversal agents for direct-acting oral anticoagulants (DOAC). Thus, the increasing number of research activities is boosting the drug discovery activities and offering lucrative opportunities for the market growth across the industry.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the anticoagulant reversal drugs market. The Middle East and Africa anticoagulant reversal drugs market is expected to grow at a good CAGR during the forecast period.

Middle East and Africa Anticoagulant Reversal Drug Market Segmentation   

By Product

• Prothrombin Complex Concentrates
• Vitamin K
• Protamine
• Tranexamic Acid
• Idarucizumab
• AndeXXa

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Country

• Middle East and Africa

  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East and Africa

Companies Mentioned

• Boehringer Ingelheim International GmbH
• Pfizer Inc
• Octapharma AG
• Fresenius Kabi AG
• Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
• CSL Limited
• Grifols, S.A.

Middle East and Africa Anticoagulant Reversal Drug Report Scope